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The importance of the p53 protein in the cellular
response to DNA damage is well known, but its func-
tion during steady-state hematopoiesis has not been
established. We have defined a critical role of p53
in regulating hematopoietic stem cell quiescence,
especially in promoting the enhanced quiescence
seen in HSCs that lack the MEF/ELF4 transcription
factor. Transcription profiling of HSCs isolated from
wild-type and p53 null mice identified Gfi-1 and
Necdin as p53 target genes, and using lentiviral
vectors to upregulate or knockdown the expression
of these genes, we show their importance in regu-
lating HSC quiescence. Establishing the role of p53
(and its target genes) in controlling the cell-cycle
entry of HSCs may lead to therapeutic strategies
capable of eliminating quiescent cancer (stem) cells.
INTRODUCTION
Hematopoietic stem cells (HSCs) can remain quiescent or they
can enter the cell cycle and either self-renew or differentiate
into multiple lineages. Although relatively quiescent, the HSC
population must give rise to a hierarchy of differentiating progen-
itor cell populations that can replenish the blood system each
day (Attar and Scadden, 2004). Blood cell production must
also respond efficiently to hematologic stresses, such as blood
loss, infection, or exposure to cytotoxic agents, via expansion
of the HSC and/or progenitor cell populations (Passegue´ et al.,
2005). These processes must occur without depleting the stem
cell pool (Venezia et al., 2004; Forsberg et al., 2005).
HSC quiescence is likely controlled by both HSC-intrinsic
mechanisms and bone marrow microenvironmental factors (Wil-
son and Trumpp, 2006). Several transcription factors have been
shown to play key roles in HSC-fate decisions. Gfi-1 has been
shown to restrict HSC proliferation and preserve HSC functional
integrity (Hock et al., 2004; Zeng et al., 2004). HOXB4 and
GATA-2 regulate HSC self-renewal (Krosl et al., 2003; Ling
et al., 2004),whereas theEts transcription factorMEF/ELF4 regu-
lates both HSC self-renewal and quiescence (Lacorazza et al.,
2006). Mef null mice exhibit greater numbers of HSCs (i.e., LSK
cells), and Mef null LSK cells are more quiescent than normal.
Early studies suggested a role for p21 in restricting HSC entry
into the cell cycle and regulating HSCpool size andHSC exhaus-tion under stress (Cheng et al., 2000). However, the regulation of
HSC self-renewal by p21 under steady-state conditions may be
minimal (van Os et al., 2007). Several studies have implicated
both the Ang-1/Tie2 and the thrombopoietin/MPL signaling path-
ways inmaintaining HSC quiescence (Arai et al., 2004; Yoshihara
et al., 2007; Qian et al., 2007).
The p53 tumor suppressor gene may regulate various aspects
of hematopoietic cell behavior (Wlodarski et al., 1998; TeKippe
et al., 2003; Chen et al., 2008; Akala et al., 2008). Although hema-
topoiesis in p53 knockout mice appears to proceed normally,
numerous studies have identified roles for p53 in the prolifera-
tion, differentiation, apoptosis, and aging of hematopoietic cells
(Shounan et al., 1996; Shaulsky et al., 1991; Kastan et al., 1991;
Lotem and Sachs, 1993; Guzman et al., 2002; Park et al., 2003;
Dumble et al., 2007). Moreover, p53 deletions and mutations
have been found at high frequency in blast crisis chronicmyelog-
enous leukemia and with some frequency in acute leukemia
(Prokocimer and Rotter, 1994). In response to DNA damage,
p53 can either elicit cell-cycle arrest or apoptosis, the typical
outcome for mature hematopoietic cells (Wu et al., 2005). But
p53 has recently been shown to negatively regulate neural
stem cell proliferation and self-renewal (Meletis et al., 2006),
and given that long-term reconstituting HSCs (LT-HSC) express
high levels of p53 transcripts (Forsberg et al., 2005 and our data,
see below), we examined the function of p53 during steady-state
hematopoiesis. We find an important interdependency between
MEF/ELF4 and p53 on HSC quiescence and identify two p53
target genes, Gfi-1 and Necdin, that regulate quiescence in
wild-type (and Mef null) HSCs. Our findings identify distinct roles
for p53 in resting versus cycling cells.
RESULTS
Maintaining HSC Quiescence by p53
Wehave recently found thatMef/Elf4 nullmouseembryonic fibro-
blasts (mefs) accumulate p53 protein and undergo premature
senescence, which appears to be due to the ability of Mef to
directly upregulate Mdm2 expression (G.S., Y.L., S.E.E., Y.M.,
K. Ohyashiki, S.M., S.D.N., unpublished data). We hypothesized
that p53 could play a role in the enhanced stem cell quiescence
(or the increased HSC frequency) seen in Mef null mice, so we
examined p53 mRNA expression in primitive Lin–Sca-1+c-Kit+
(LSK) cells and in various myeloid progenitor cells (CMP, GMP,
and MEP). p53 is most highly expressed in LSK cells (Figure S1
available online), suggesting that it could play an important role
in HSC physiology.Cell Stem Cell 4, 37–48, January 9, 2009 ª2009 Elsevier Inc. 37
Cell Stem Cell
p53 Maintains HSC QuiescenceFigure 1. Maintenance of HSC Quiescence by p53
(A) Multicolor flow cytometry was used to determine the percentage of hematopoietic stem/progenitor cells (Lin–Sca-1+) in the G0 phase of the cell cycle (defined
as cells with low Pyronin Y content that contain 2 n DNA [G0/G1]). Total bone marrow cells from wild-type and p53/ mice were stained with Pyronin Y and
Hoechst 33342. One representative experiment is shown on the left. The graph on the right indicates the mean percentage (±SD) of G0 cells present (p <
0.005, n = 9).
(B) Side population (SP) cells (CD34LSKs) from wild-type and p53/mice were identified by Hoechst 33342 staining and the use of blue and red filters. The bar
graph on the right indicates the mean percentage (±SD) of SP cells present (p < 0.003, n = 7).
(C) Cell-cycle analysis of CD34LSK cells was performed by staining with Hoechst 33342 and Ki67 and analyzed by FACS. Data shown are the mean values ± SD
(p < 0.0001, n = 9).
(D) The proliferation of CD34LSK cells was measured by in vivo BrdU incorporation over 48 hr. Greater proliferation of p53/ CD34LSK cells was seen (60%
versus 30% for wild-type CD34LSK cells; p < 0.009, n = 5).We then examined the cell-cycle status of p53/ Lin–Sca-1+
cells using Pyronin Y and Hoechst 33342 staining and observed
a reduction of Pyronin Ylow cells, indicating the presence of fewer
quiescent HSCs (p < 0.005, Figure 1A). Using the SP phenotype
as a marker for quiescent HSCs in adult bone marrow (Goodell
et al., 1996; Arai et al., 2004), we also found a 2-fold decrease
in the frequency of CD34–LSK SP cells in the absence of p53
(p < 0.003, Figure 1B). Staining of p53 null CD34–LSK cells with
the proliferation marker Ki67 also showed enhanced HSC prolif-
eration with fewer quiescent cells present (p < 0.001, Figure 1C).
Furthermore, to determine the proliferative rate of p53 /
CD34LSK cells in vivo, we administered BrdU to mice orally
for 2 days and isolated CD34LSK cells from the bone marrow.38 Cell Stem Cell 4, 37–48, January 9, 2009 ª2009 Elsevier Inc.While 30% of wild-type CD34LSK cells incorporated BrdU
over this period, 60% of the p53 / CD34LSK cells were
BrdU positive (Figure 1D, p < 0.01; and Figure S2). These data
suggest that p53 promotes HSC quiescence, and in its absence,
HSCs more easily enter the cell cycle.
Role of p53 in HSCs ofMef/ Mice
Given the HSC phenotype of the p53 null mice and the upregu-
lation of p53 in Mef null fibroblasts, we generated p53/Mef/
mice to determine both the frequency and the cell-cycle status of
the hematopoietic stem (and progenitor) cells. Loss of MEF
alone, p53 alone, or both MEF and p53 increased the frequency
of LSK cells (2- to 3-fold) compared towild-typemice (Figure 2A).
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p53 Maintains HSC QuiescenceFigure 2. Increased HSC Frequency in p53/Mef/ Mice
(A) Increased LSK cell frequency in p53/Mef/mice. Lin–Sca-1+c-Kit+ cells were quantified by flow cytometry. Data shown are the mean percentage (±SD) of
LSK cells in the marrow (p < 0.0002, n = 13).
(B) Increased LT-HSC frequency in the marrow of p53/Mef/ mice. The frequency of LT-HSCs (CD150+Sca-1+c-kit+CD41CD48Lin) was defined by flow
cytometric analysis of SLAM cell surface markers. p53 /, Mef/, and p53 /Mef/ mice all showed a significant increase in the frequency of
CD150+CD41CD48LSK cells, which correspond to LT-HSCs. Data shown are the mean percentage (±SD) of LT-HSCs (n = 10).
(C) Bone marrow cells from wild-type, p53/,Mef/, and p53/Mef/mice were stained with stem and progenitor cell surface markers, and apoptosis was
assessed using PI and Annexin-V staining. Data shown aremean percentage (±SD) of Annexin-V+/PI– LSK cells (p = 0.2 by ANOVA; i.e., statistically not significant,
n = 5).This small but consistent increase in HSC frequency was
confirmed using the SLAM cell surface makers, as we also
observed a consistent 2-fold increase in the frequency of
CD150+CD41CD48Sca-1+c-kit+Lin cells (LT-HSCs) in the
bone marrow of mice lacking MEF, p53, or both MEF and p53
compared to wild-type mice (Figure 2B). The increased HSC
numbers could be due to enhanced self-renewal or to decreased
apoptosis. We evaluated cell survival by Annexin-V staining and
found no significant difference in the number of apoptotic (An-
nexin-V+/PI–) HSCs in the wild-type and p53/Mef/ mice at
steady state (Figure 2C). Thus, the increase in HSCs appears
to be due to enhanced self-renewal.
The Increased HSC Self-Renewal Capacity of Mef Null
Mice Does Not Depend on p53
To define how loss of p53 (and MEF) affects HSC behavior, we
performed in vitro (cobblestone area-forming cell [CAFC], long-
term culture-initiating cell [LTC-IC], and serial replating assays)
and in vivo (serial bone marrow transplantation and competitiverepopulation) functional assays. p53/ bone marrow cells
contain 5-fold more CAFCs compared to wild-type bonemarrow
cells, and this increased CAFC frequency is also seen in p53/
Mef/ bone marrow (Figure 3A). Similar findings were seen in
the LTC-IC assay, as p53/ LSK cells formed 5-fold more
colonies than did wild-type LSK cells. However, the Mef/ and
the p53/Mef/ LSK cells formed 10-fold more colonies than
the wild-type LSK cells (Figure 3B).
In the serial replating assay, which assesses the preservation
of ‘‘stemness’’ in the progenitor cell compartment, wild-type
BMMCs cannot be replated more than three times. Hematopoi-
etic progenitor cells that lackMef show increased serial replating
in CFU assays, confirming our earlier findings (Lacorazza et al.,
2006), and so do the p53/ and the p53/Mef/BMMCs (Fig-
ure 3C). Thus, loss of p53 showed effects in wild-type HSCs but
no detrimental effect on HSC frequency in the Mef null back-
ground in any of these in vitro assays.
To assess whether the accumulation of HSCs in p53/Mef/
mice reflects increased self-renewal, we began serial boneCell Stem Cell 4, 37–48, January 9, 2009 ª2009 Elsevier Inc. 39
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p53 Maintains HSC QuiescenceFigure 3. The Increased HSC Self-Renewal Capacity of Mef Null Mice Does Not Depend on p53
(A) The steady-state level of bonemarrow cobblestone area-forming cells was evaluated by scoring colonies at week 5. Data shown aremean values (±SD) (n = 3).
(B) LSK cells (13 103) from wild-type, p53/,Mef/, and p53/Mef/mice were cultured on MS5 stromal cells for 4 weeks and tested for colony formation in
the LTC-IC assay. Data shown are the mean number (±SD) of colonies formed (n = 3).
(C) Serial replating studies. Myeloid progenitors were quantified by methycellulose culture using BMMCs from wild-type, p53/, Mef/, and p53/Mef/
mice. The methycellulose cultures were serially replated, weekly, for 4 weeks. Mean values (±SD) shown (n = 3).
(D) Lethally irradiated recipient mice (CD45.1) were transplanted with 13 103 LSK cells fromwild-type, p53/,Mef/, and p53/Mef/mice (CD45.2) plus 53
105 competitor cells (CD45.1) in competitive repopulation assays (described in the Experimental Procedures). The bar graph on the right shows the mean
percentage (±SD) of donor-derived (CD45.2) cells in the peripheral blood 16 weeks posttransplantation (n = 4).
(E) The LTC-IC assay was used to enumerate primitive hematopoietic stem cells, using limiting dilutions of LSK cells that were first cultured for 5 weeks on MS5
stroma and then cultured on methylcellulose for the readout. The number of wells that lacked LTC-ICs is graphed versus the number of LSK cells per well.marrow transplant (sBMT) assays using BMMCs from each
genotype (wild-type, p53/, Mef/, p53/Mef/, C57BL/6,
and CD45.2) of mice as donor cells and lethally irradiated mice
(CD45.1) as recipients. However, most of the recipient mice
transplanted with p53/ BMMCs died within 4 months post-
transplant due to the development of lymphomas, and although
recipient mice transplanted with p53/Mef/ BMMCs lived
longer, most of them died within 5 months of transplantation.
Thus, we could not perform serial bone marrow transplantation.
Instead, we performed competitive repopulating experiments,
transplanting 1000 LSK cells of each genotype (wild-type,
p53/, Mef/, p53/Mef /, and CD45.2) into lethally irradi-
ated (9.5 Gy) B6.SJL recipient mice (CD45.1) along with a
constant, small dose (5 3 105) of competitor marrow cells
(CD45.1). At 16 weeks posttransplantation, the repopulating
abilities of both the Mef/ and p53/Mef/ cells were many
fold higher than the wild-type cells, while loss of p53 had
a modest effect on competitive repopulating ability (Figure 3D).
To further assess HSC frequency, we performed long-term
culture-initiating cell (LTC-IC) assays, under limiting dilution
conditions, a stringent assay that correlates with the in vivo repo-
pulating potential of primitive hematopoietic progenitor cells
(Ploemacher et al., 1991). The increased frequencies of primitive
HSCs in Mef/, p53/, or p53/Mef/ mice were also
evident in the LTC-IC assay (Figure 3E). Thus, the enhanced40 Cell Stem Cell 4, 37–48, January 9, 2009 ª2009 Elsevier Inc.self-renewal potential of Mef/ HSCs is not dependent on the
presence of p53.
p53 Is Essential for Maintaining Hematopoietic Stem
Cell Quiescence in Mef Null Mice
We assessed HSC quiescence in the various genetic back-
grounds under homeostatic conditions and confirmed the
increased quiescence ofMef null HSCs (Figure 4A).We observed
a small but consistent decrease in the quiescence of p53/
HSCs but found that the enhanced quiescence of Mef null
HSCs was abrogated by the absence of p53 (analyzing the
p53/Mef/ mice). By using the SP phenotype as a marker
for quiescent HSCs in adult bone marrow (Arai et al., 2004), we
found that p53 loss not only leads to a 2-fold decrease in
CD34–LSK SP cells in wild-type mice (Figure 1B), but that its
absence in Mef null CD34–LSK SP cells returns the frequency
of these cells in the bone marrow to normal (Figure 4B). Thus,
p53 is required for the enhanced stem cell quiescence seen in
Mef null mice.
Mef null bone marrow is relatively resistant to radiation (and
chemotherapy), an effect that we attributed to the enhanced
HSC quiescence (Lacorazza et al., 2006). To assess the effects
of both Mef and p53 loss on the response of HSCs to total
body irradiation (6.5 Gy), we harvested bone marrow cells 12 hr
postirradiation and assayed for apoptosis of LSK cells by
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p53 Maintains HSC QuiescenceFigure 4. p53 Is Essential for Maintaining Hematopoietic Stem Cell Quiescence in Mef Null Mice
(A) Multicolor flow cytometry was used to determine the percentage of Lin–Sca-1+ cells in the G0 phase of the cell cycle (defined as cells with low Pyronin Y
content that contain 2 n DNA [G0/G1]). Data shown are the mean percentage (±SD) (n = 6).
(B) Analysis of SP cells within the CD34–LSK cells. CD34–LSK cells from wild-type, p53/,Mef/, and p53/Mef/mice were examined for the proportion of
SP cells. Data shown are the mean percentage (±SD) of SP cells (n = 3).
(C) Bonemarrow cells fromwild-type, p53/,Mef/, and p53/Mef/mice obtained 12 hr after a dose of total-body irradiation (TBI, 6.5 Gy) were assessed for
apoptosis using PI and Annexin-V staining. Data shown are mean percentage (±SD) of Annexin-V+/PILSK cells (n = 3).
(D) g-H2AX foci generation in HSCs following irradiation. LSK cells from wild-type, p53/,Mef/, and p53/Mef/mice were immunostained for g-H2AX 3 hr
after irradiation (200 rads) (and DAPI stained to identify the nuclei). The bar graph at the bottom shows the percentage of LSK cells that show 0–2, 3–5, or >5 foci
(200 cells are counted in each genotype).Annexin-V staining. As expected, LSK cells from both the p53/
mice and the Mef/ mice showed decreased apoptosis after
radiation. However, LSK cells from the p53/Mef/ mice ex-
hibited normal radiation-induced apoptosis (Figure 4C), implying
that abrogating the enhanced HSC quiescence in the Mef/
mice is more important in defining radio-sensitivity than is
abrogating p53-dependent apoptosis.
As phosphorylation of histone H2AX (g-H2AX) is an indicator
of DNA damage (Rossi et al., 2007), we irradiated wild-type,
p53/, Mef/, and p53/Mef/ mice (2 Gy) and quantified
the number of g-H2AX foci in individual HSCs using immunos-
taining. We found that HSCs from Mef/ mice were largelydevoid of g-H2AX foci (15% cells stain positive for 3–5 foci of
g-H2AX and none for >5 foci), while more than 30% of the
HSCs from wild-type, p53/, and p53/Mef/ mice stained
positively for g-H2AX (Figure 4D). These data further indicate
that the relative radioresistance of HSCs from Mef/ mice,
like the enhanced quiescence, requires the presence of p53.
HSC Quiescence in Mef Null Mice Does
Not Depend on p21
p21 is a major target gene of p53, and in the absence of p21,
HSC numbers and proliferation are reported to be increased,
leading to stem cell exhaustion following serial bone marrowCell Stem Cell 4, 37–48, January 9, 2009 ª2009 Elsevier Inc. 41
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p53 Maintains HSC QuiescenceFigure 5. Enhanced HSC Quiescence in Mef Null Mice Does Not Depend on p21
(A) Increased p21 and p27 expression inMef/ LSK cells. The relative mRNA expression level of p21, p27, and p16 in LSK cells from wild-type andMef/mice
were evaluated by qPCR and normalized to HPRT expression. Data shown are the mean ratio (±SD) of transcript levels over HPRT (n = 2).
(B) Multicolor flow cytometry was used to determine the percentage of hematopoietic stem cells in the G0 phase of the cell cycle. LinSca-1+ cells in G0 phase are
defined as cells with low Pyronin Y content that contain 2n DNA (G0/G1). The bar graph on the right shows the mean percentage (±SD) (n = 5).
(C) Cell-cycle analysis of LSK cells from wild-type, p21/, Mef/, and p21/Mef/ mice. Cells were stained with Hoechst 33342 and Ki67 and analyzed by
FACS. Data shown are the mean percentage (±SD) (n = 6).
(D) g-H2AX foci generation in HSCs following irradiation. LSKs fromwild-type, p21/,Mef/, and p21/Mef/mice were immunostained for g-H2AX 3 hr after
irradiation (200 rads). DAPI staining was used to identify the nuclei. The bar graph at the bottom shows the percentage of LSK cells that show 0–2, 3–5, or >5 foci
(200 cells are counted for each genotype).transplantation (Cheng et al., 2000). As Mef null LSK cells show
increased quiescence, we first examined whether p21 expres-
sion is upregulated in Mef/ HSCs and could account for their
enhanced quiescence (and for the effect that loss of p53 has
on HSC quiescence). Real-time PCR analysis determined that
the level of p21 expression is several-fold higher in Mef/
HSCs than in wild-type HSCs; p27 is modestly upregulated
and p16 is downregulated (Figure 5A).
We then generated p21/Mef/mice, which are viable, born
at normal Mendelian frequency, and appear grossly normal.
Based on Pyronin Y and Hoechst 33342 staining, we found no
effect of p21 loss on the enhanced HSC quiescence generated
by the lack of Mef (Figure 5B). Furthermore, the aberrantly high42 Cell Stem Cell 4, 37–48, January 9, 2009 ª2009 Elsevier Inc.proportion of noncycling (Ki67–) LSK cells seen in the Mef/
mice was also seen in the p21/Mef/ mice (Figure 5C and
Figure S3). Thus, the increased quiescence of Mef null HSCs is
not dependent on p21.
To further address whether the relative radioresistance of the
Mef null HSCs reflected their quiescence status, we irradiated
wild-type, p21/, Mef/, and p21/Mef/ mice (2 Gy) and
quantified the number of g-H2AX foci in individual HSCs.
HSCs from bothMef/ and p21/Mef/mice hadmany fewer
g-H2AX foci than HSCs from either wild-type or p21/ mice
(Figure 5D). Thus, the relative radioresistance of HSCs inMef/
mice, like the enhanced quiescence, does not require the
presence of p21.
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p53 Maintains HSC QuiescenceGfi-1 and Necdin Are Direct Transcriptional Targets
of p53 and Mediate Its Effects in HSCs
The quiescent state of Mef null HSCs is p53 dependent but p21
independent, which implies that other p53 target genes are
involved in maintaining stem cell quiescence. To identify such
p53 targets, we performed transcript profiling (using microarray
studies and quantitative real-time PCR analysis) to compare
gene expression in LSK cells isolated from wild-type, p53/,
and p53/Mef/ mice. We also utilized Ingenuity Pathways
Analysis software to group potential p53 target genes into
specific pathways that may be important in HSC behavior. We
identified several putative p53 target genes (that are differentially
expressed in both p53/ and p53/Mef/ cells compared to
wild-type cells) and several signaling pathways that appear to
be altered in the absence of p53 (Figure 6A and Figure S6).
Two genes drew our initial attention: Gfi-1 and Necdin. Gfi-1
(growth factor independent-1) is a zinc finger containing a tran-
scriptional repressor that has been shown to restrict HSC prolif-
eration and preserve HSC functional integrity (Hock et al., 2004;
Zeng et al., 2004). Necdin is another growth suppressor. It acts
as a negative cell-cycle regulator in postmitotic neurons and
contributes to their permanent mitotic arrest (Hu et al., 2003;
Taniura et al., 1999, 2005; Yoshikawa, 2000); necdin is known
to be highly expressed in LT-HSCs (Forsberg et al., 2005).
We first confirmed the marked increase of Gfi-1 and Necdin
mRNA in Mef/ LSK cells by real-time PCR analysis (shown in
Figure 6B). To determine whether Gfi-1 and Necdin are direct
targets of p53, we scrutinized the DNA sequence of the mouse
and human Gfi-1 and Necdin genes and found two conserved
potential p53 binding sites (p53 RE1 and p53 RE2) in the Gfi-1
promoter and one conserved p53 binding site in the Necdin
promoter. To assess whether any of these sites are essential
for p53-mediated activation, each site was individually mutated
in a luciferase reporter plasmid: p53 strongly transactivated
the Necdin promoter, and point mutations in the consensus
p53 binding site abolished p53-mediated promoter activation
(Figure 6C). p53 also transactivated the Gfi-1 promoter 5-fold.
Mutations in the p53 RE1, but not the p53 RE2, abolished p53-
mediated Gfi-1 promoter activation, implying that only the p53
RE1 is required for the p53 responsiveness of theGfi-1 promoter.
Next, to determine whether endogenous p53 is bound to the
Gfi-1 and Necdin promoters in vivo, we performed chromatin
immunoprecipitation (ChiP) assays and observed binding of
p53 to both theGfi-1 and Necdin promoters in Lin– bone marrow
cells (Figure 6D). Thus, p53 directly binds the Gfi-1 and Necdin
promoters and activates their expression.
The Role of Necdin in Hematopoiesis
To examine whether Gfi-1 and Necdin are responsible for the
enhanced quiescence ofMef null HSCs, we acutely lowered their
expression in Lin–Sca-1+ cells, using siRNA. First, we reduced
the level of both Gfi-1 and Necdin mRNA and found significant
reduction in the quiescence of theMef/HSCs cells (Figure 6E),
indicating that these p53 target genes are functionally important
in HSCs.
While Gfi-1 is a known regulator of HSC proliferation (Hock
et al., 2004), the function of Necdin in regulating quiescence in
normal HSCs has not been described. To further investigate its
role in HSC biology, we measured Necdin mRNA levels in LSKcells (and in a variety of committed myeloid progenitor cells);
Only the LSK cells had significant Necdin expression (Figure S7).
Then, we reduced Necdin expression in wild-type Lin–Sca-1+
cells using siRNA and also overexpressed Necdin in Lin–Sca-1+
cells using lentiviral gene transfer. HSC quiescence decreased
when Necdin was knocked down and increased when we over-
expressed Necdin (based on the percentage of Lin–Sca-1+ cells
in the G0 phase of the cell cycle, Figures 7A and 7B). Thus,
Necdin appears to be a true regulator of HSC quiescence.
To examine if Necdin also regulates HSC self-renewal, we
knocked-down Necdin expression in mouse bone marrow cells
using lentivirally expressedshRNAandperformed invitroserial re-
plating assays. The downregulation of Necdin in wild-type bone
marrow cells significantly increased colony numbers at week 1
and, to a greater extent, in weeks 2 and 3 (Figure 7C). Thus, like
p53, Necdin also regulates the maintenance of HSC self-renewal
capability, recapitulating another effect of p53 on HSC biology.
DISCUSSION
p53 plays critical roles in triggering senescence, apoptosis and
cell cycle arrest in virtually all cell types (Vousden and Lane,
2007). We have investigated its role in hematopoietic stem/
progenitor cells (i.e., LSK cells) and have found effects on HSC
quiescence and self-renewal. Using a variety of in vivo and
in vitro assays, we have shown that HSC quiescence is impaired
in the absence of p53 and that p53 function is essential for the
enhanced stem cell quiescence seen in Mef null mice.
p53-dependent downstream responses have been shown to
be mediated by specific target genes, such as p21, BTG2,
BAX, and PUMA (Zhao et al., 2000; Boiko et al., 2006; Meletis
et al., 2006). Comparative transcript profiling has allowed us to
identify a variety of p53 target genes in HSCs; some of these
genes are inversely regulated by MEF, suggesting that p53 func-
tion is enhanced in the absence of MEF. To our surprise, the
increased stem cell quiescence observed in Mef null mice is
not dependent on p21, despite its elevated level, which promp-
ted us to look for other p53 target genes that could play this role.
To identify such p53 targets, we compared gene expression in
LSK cells isolated from wild-type, p53/, and p53/Mef/
mice and identified several potential regulators of HSC self-
renewal and proliferation that were differentially expressed
between wild-type and p53/ HSCs (Figure 6A). The expression
of two of these genes (CCNG1 andSERPINE2) was previously re-
ported tobecontrolledbyp53, validating theapproach.However,
themajority of differentially expressed genes have not been impli-
cated as p53 targets. Some of the differentially expressed genes
fit into signaling pathways that may affect HSC maintenance,
such as Wnt, p38 MAPK signaling, PTEN signaling, and cytokine
signaling (Chambers et al., 2007). For example, SOCS3 downre-
gulates cytokine signaling, and the Wnt receptor FZD7 has been
implicated in the self-renewal of human embryonic stem cells
(Melchior et al., 2008); both are upregulated in p53/ and p53/
Mef/ HSCs and could play a role in the regulation of HSC
behavior (Figure 6A). Caspase-3, a downstream target of the
PTEN/Akt pathway recently implicated in regulating the respon-
siveness of HSCs to exogenous signals (Janzen et al., 2008), is
also upregulated in both p53/ and p53/Mef/ HSCs. Thus,
caspase-3 upregulation may also contribute to the enhancedCell Stem Cell 4, 37–48, January 9, 2009 ª2009 Elsevier Inc. 43
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p53 Maintains HSC QuiescenceFigure 6. Gfi-1 and Necdin Are Direct Transcriptional Targets and Functional Mediators of p53 in HSCs
(A) Transcript profiling of LSK cells isolated from wild-type, p53/, p53/Mef/ mice were analyzed by Affymetrix oligonucleotide array. Genes that are
differentially expressed in both p53/ and p53/Mef/ HSCs compared to wild-type cells are shown. We utilized Ingenuity Pathways Analysis (Ingenuity
Systems) to group genes into specific canonical pathways. FC stands for fold change.
(B) Increased Gfi-1 and Necdin expression in Mef/ LSK cells. The relative mRNA expression level of p16, p21, Gfi-1, and Necdin in LSK cells from wild-type,
Mef/ and, p53/Mef/micewere evaluated by qPCR and normalized to HPRT expression. Data shown are themean ratio (±SD) of transcript levels relative to
HPRT (n = 2).
(C) p53 transactivates both the Necdin and Gfi-1 promoters. HeLa cells were transfected with Necdin promoter- or Gfi-1 promoter-driven luciferase reporter
plasmids containing either wild-type p53 binding sites or mutant p53 binding sites. Luciferase activity was assayed 24 hr after transfection. Values are means
(±SD) (n = 3).
(D) p53 binds to the Gfi-1 andNdn promoters in vivo. Chromatin bound DNA from Lin– bonemarrow cells was immunoprecipitated with a p53-specific antibody or
with normal mouse IgG. qPCR amplification was performed on corresponding templates using primers for the Gfi-1, Necdin, or p21 genes.
(E) Downregulation of Gfi-1 and Necdin expression in Mef/ cells decreases HSC quiescence. Mef/ Lin–Sca-1+ cells were nucleofected with control, Gfi-1
or Necdin siRNAs. Twenty-four hours postnucleofection, cells were stained with Pyronin Y and Hoechst 33342 and analyzed by FACS. Values are means
(±SD) (p < 0.004, n = 5). The effectiveness of the knockdown for each siRNA (versus control siRNA) is shown on the right.44 Cell Stem Cell 4, 37–48, January 9, 2009 ª2009 Elsevier Inc.
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p53 Maintains HSC Quiescenceself-renewal of p53/HSCs.While changes in the levels of these
genes may alter HSC behavior, we expect that no one p53 target
will be absolutely essential for its effect on quiescence. While we
have identified genes that are differentially expressed between
p53/ and p53/Mef/ HSCs, these genes are likely to be
regulated by MEF/ELF4, and they will not be further discussed.
There is accumulating evidence for the role of tumor
suppressor genes and oncogenes in stem cell maintenance
and cell cycle regulation. While our transcript profiling of hema-
topoietic stem cells lacking p53 provides an overview of the
pathways that may be important for HSC quiescence and self-
renewal, pathways not yet implicated in regulating HSC behavior
may still play an important role. As not all hematopoietic proteins
are identified by the pathway analysis software, we have focused
primarily on Necdin, a negative regulator of the cell cycle (Hu
et al., 2003; Taniura et al., 1999, 2005; Yoshikawa, 2000) that
is highly expressed in HSCs (Figure S7 and Forsberg et al.,
2005). We find that the enhanced quiescence exhibited in Mef
null HSCs is, at least in part, mediated by Necdin. Furthermore,
downregulating Necdin diminishes HSC quiescence, and upre-
gulating Necdin increases HSC quiescence, identifying its role
as a rheostat controlling HSC quiescence (Figures 7A and 7B).
Necdin and p53 have been shown to inhibit cell growth in an
additive manner (Taniura et al., 1999), suggesting the presence
of a positive feedback loop that may control the quiescent state
(Figure S6). While disruption of the mouse necdin gene results in
early postnatal lethality with variable penetrance in C57BL/6
background (Ge´rard et al., 1999;Muscatelli et al., 2000), no post-
natal lethality is seen in the ICR strain background (Kuwako et al.,
2005). Analysis of HSC behavior in necdin-deficient mice will
further define the role of necdin in fetal and/or adult hematopoi-
esis.Gfi-1 is another p53 target identified in ourChiP and reporter
gene assays. TheGfi-1 locus is among themost frequent sites for
retroviral integration contributing to the development of lymphoid
tumors in mice (Zhu et al., 2002); its role in HSCs is well docu-
Figure 7. Necdin Functions as a Rheostat to Regulate
HSC Quiescence and Maintenance
(A) Effect of downregulating Necdin expression on HSC quies-
cence. Wild-type Lin– cells were nucleofected with control or Nec-
din siRNAs. Twenty-four hours postnucleofection, the cells were
stained with Pyronin Y and Hoechst 33342 and analyzed by
FACS. Values are means (±SD) (p < 0.04, n = 2).
(B) Effect of overexpressing Necdin on HSC quiescence. Wild-
type Lin– cells were infected with control or Necdin-expressing
lentiviruses. Forty-eight hours postinfection, the cells were stained
with Pyronin Y and Hoechst 33342 and analyzed by FACS. Values
shown are the means (±SD) (p < 0.02, n = 3).
(C) Effects of downregulating Necdin expression on serial replat-
ing of hematopoietic stem/progenitor cells in methycellulose
assays. Values shown are means (±SD) (n = 3).
mented (Hock et al., 2004; Zeng et al., 2004). However,
we have identified Gfi-1 as a direct transcriptional
target of p53 in HSCs and confirm its importance in
regulating cell-cycle progression in these cells.
Using g-H2AX foci formation as an indicator of DNA
damage (Rossi et al., 2007), we found that LT-HSCs
(CD34–LSKs) formed less g-H2AX foci than ST-HSCs
(CD34+LSKs) (Figure S4). LT-HSCsaremorequiescent
than ST-HSCs (Passegue´ et al., 2005); thus, g-H2AX foci forma-
tion in HSCs seems to correlate with the quiescent status of the
cell. Consistent with the enhanced quiescence of Mef/ HSCs,
we found that only 15% HSCs from Mef/ mice formed
g-H2AX foci after irradiation, compared to 56% of the HSCs
from p53/Mef/ mice, which are less quiescent. Mef null
LSKs undergo less apoptosis than wild-type LSKs after irradia-
tion, whereas Mef/p53/ LSKs show normal radiosensitivity.
Thus, HSC quiescence tracks with radioresistance in both the
Mef null and Mef/p53 double null mice. We would predict that
because the enhanced HSC quiescence is maintained in the
p21/Mef/mice, the enhanced recovery frommyelosuppres-
sive treatments seen in Mef/ mice should also be preserved.
Indeed, we find that p21/Mef/ mice have less leukopenia
following a single dose of 5-flurouracil (5-FU) than wild-type
mice and more rapid recovery (Figure S5), a pattern identical to
that seen for the Mef/ mice. Thus, p21 is not essential for the
relative quiescence or the chemoresistance seen in Mef null
mice. These findings provide additional proof that the resistance
of HSCs to irradiation, or chemotherapy agents, depends
strongly on their quiescent properties.
HSCs are sensitive to reactive oxygen species (ROS), as
elevated ROS levels can limit the life span of HSCs in vivo (Ito
et al., 2006). Loss of p53 function in normal cells increases intra-
cellular levels of ROS, which leads to increased DNA damage
and an increased mutation rate (Sablina et al., 2005). The relative
quiescence of LT-HSCs may protect these cells from DNA
damage caused by ROS, chemotherapy drugs, or irradiation.
Avoiding inheritable damage would be particularly important
for stem cells, and a cytoprotective function of p53 in the
hematopoietic compartment, mediated by its effects on HSC
quiescence, would help maintain HSC integrity.
We have established a role of p53 in steady-state hematopoi-
esis which is more profoundly seen in the absence of Mef. Our
report adds to the evidence that p53 negatively regulates HSCCell Stem Cell 4, 37–48, January 9, 2009 ª2009 Elsevier Inc. 45
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p53 Maintains HSC Quiescenceself-renewal (TeKippe et al., 2003; Chen et al., 2008; Akala et al.,
2008), as we too find that p53/ mice have more immunophe-
notypic HSCs. But we also found that p53/ mice have more
functional HSCs as measured by a variety of in vitro and in vivo
assays. Additionally, the enhanced self-renewal of Mef/
HSCs does not depend on the presence of p53 (Figure 3), sug-
gesting that other self-renewal regulators mediate this effect.
As p53 has been shown to negatively regulate proliferation and
self-renewal of neural stem cells (Meletis et al., 2006), our work
provides additional proof that neural stem cells and hematopoi-
etic stem cells utilize common pathways to maintain their stem
cell compartment (Molofsky et al., 2003; Park et al., 2003;
Groszer et al., 2006; Yilmaz et al., 2006; Zhang et al., 2006).
Mutations within the stem cell can ultimately lead to the gener-
ation of leukemic stem cells, which often retain many character-
istics of normal hematopoietic stem cells such as a hierarchical
developmental pattern, a mostly quiescent cell-cycle profile,
and an immunophenotype very similar to HSCs (Jordan and
Guzman, 2004; Jin et al., 2006; Komarova and Wodarz, 2007).
The tumor suppressor gene p53 is the most mutated gene in
human cancer, and further study is needed to determine whether
gain-of-function p53 mutations that contribute to chemotherapy
and radiation therapy resistance still promote the quiescence of
hematopoietic stem cells. Our findings have important implica-
tions for HSCs homeostasis during steady-state hematopoiesis
and for developing therapeutic strategies that could eliminate
the largely quiescent cancer stem cell.
EXPERIMENTAL PROCEDURES
Mice
The generation of Mef-deficient mice was described previously (Lacorazza
et al., 2006). p21/ mice (129/sv) were kindly provided by Tyler Jacks and
p53+/ mice (C57BL/6, CD45.2) by Carlos Cordon-Cardo. p21/Mef/
mice were generated by interbreeding p21/ female with Mef/ male
mice, and p53/Mef/ (C57BL/6, CD45.2) mice were generated by inter-
breeding p53+/ female with Mef/ male mice. Wild-type C57BL/6 (CD45.2)
and B6.SJL (CD45.1) mice were purchased from Jackson Laboratories. All
mice were maintained in the MSKCC Animal Facility according to IACUC-
approved protocols and kept in Thorensten units with filtered germ-free air.
Flow Cytometry
Murine hematopoietic stem/progenitor cells (LSK cells) were identified and
evaluated by flow cytometry using a single cell suspension of bone marrow
mononuclear cells (BMMCs). BMMCs were obtained from both tibias and
femurs by flushing cells out of the bone using a syringe and DMEM + 10%
FBS. Cells were first stained with a lineage (Lin) cocktail of antibodies from
BD Biosciences (biotinylated anti-mouse antibodies directed against CD3e,
CD11b, CD45R/B220, Gr-1, and Ter119), as well as Sca-1 PE and c-kit APC
(PharMingen) and a streptavidin Cychrome conjugate (PharMingen) for
analysis using a FACScan cytometer (Becton Dickinson). c-kit APC, Sca-1
PE-Cy7, Flt3 PE, CD34 FITC, and streptavidin APC-Cy7 were used for analysis
using a Moflow cytometer (Cytomation). FITC-CD41, FITC-CD48, and FITC-
CD34 were purchased from eBioscience, and PE-CD150 was purchased
from Biolegend for SLAM marker analysis. All other antibodies were from BD
Biosciences. CMP, GMP, and MEP populations were analyzed and sorted
with a Moflow instrument (Cytomation) (Akashi et al., 2000). Nuclear staining
of Ki67 was done using an FITC-anti-human Ki67 antibody (BD PharMingen)
and fixation and permeabilization solutions from BD Biosciences.
Stem and Progenitor Cell Assays
To perform the CAFC assay, we seeded 1.53 105 bonemarrow cells ontoMS5
stroma cells and cultured the cells in aMEM containing 12.5% FBS, 12.5%46 Cell Stem Cell 4, 37–48, January 9, 2009 ª2009 Elsevier Inc.horse serum, 1 mMhydrocortisone, and 1mMglutamine. Themedia was semi-
replenished weekly, and the ‘‘cobblestone’’ colonies were scored at week 5
and expressed as the number of CAFC per 1.5 3 105 BMMCs. CAFC
frequency was determined using L-Calc software (StemCell Technologies).
For the long-term culture initiating cell (LTC-IC) assay, 1 3 103 LSK cells
were cultured on MS5 stromal cells. After 4 weeks of weekly semi-replenish-
ment of the media, cells were harvested and plated on methylcellulose media
(MethoCult GF M3434, StemCell Technologies). Clonogenic progenitors were
determined after 10 days using 2 3 104 cells per well (6-well plate). Colonies
were scored and expressed as number of the CFUs per 1 3 103 LSK cells.
For the limiting dilution LTC-IC assays, serial 5-fold dilutionswere done using
initially 125 LSKs/well; 6 replicates of each genotype (WT, p53/,Mef/, and
p53/Mef/)were performed. After 5 weeks of weekly semireplenishment of
the media, cells were trypsinized and plated onmethylcellulosemedia (Metho-
Cult GF M3434, StemCell Technologies) and cultured for 10 days before the
percentage of negative wells per dilution was scored. Frequencies were calcu-
lated using Poisson statistics (L-cal program from StemCell Technologies).
Bone Marrow Transplantation
In the competitive repopulation study, we injected 1000 LSK cells from wild-
type, Mef/, p53/, and Mef/p53/ mice (CD45.2) together with 5 3 105
competitor cells (CD45.1) into lethally irradiated B6.SJL mice (CD45.1). After
16 weeks, peripheral blood was obtained by retro-orbital eye bleeding, the
RBCs were lysed, and the PBMCs were stained with anti-CD45.2 FITC and
anti-CD45.1 PE and analyzed by flow cytometry.
g-H2AX Immunostaining
g-H2AX was revealed by using the SCIPhos (single-cell imaging of phosphor-
ylation) assay (Rossi et al., 2007). In brief, HSCs (CD34LSK and CD34+LSK)
were sorted into droplets of PBS on poly(l-lysine)-coated slides, then fixed,
permeabilized, and stainedwith phospho-specific (Ser 139) histone H2AX anti-
body (Biolegend). Fluorescence images were obtained by using a confocal
laser-scanning microscope (Olympus, model FV1000). We quantified g-H2Ax
foci number in individual stem cells and counted 200 cells in each group.
Gene Expression and Pathways Analysis
Gene expression assays were performed as described previously (Jankovic
et al., 2007), using RNAs isolated from wild-type, p53/, and p53/Mef/
LSK cells in both oligonucleotide arrays (Affymetrix) and qPCR. The DNA
sequence of all PCR primer pairs used is available upon request. Raw data
will be available for download from Gene Expression Omnibus (http://ncbi.
nlm.nih.gov/geo/, accession number GSE13448). The Affymetrix data were
analyzed using the Ingenuity Pathways Analysis program (Ingenuity Systems,
www.ingenuity.com); to identify the pathways thatmet the < or > 2-fold change
cutoff andwere associatedwith a canonical pathway in the Ingenuity Pathways
Knowledgebasewere considered for theanalysis. The significanceof theasso-
ciation between the data set and the identified canonical pathway was
measured in 2 ways: (1) A ratio of the number of genes from the data set that
map to the pathway divided by the total number of genes from the data set
that map to the canonical pathway and (2) Fischer’s exact test, to calculate
a p value determining the probability that the association between the genes
in the data set and the canonical pathway is explained by chance alone.
Electroporation of siRNAs into LinSca-1+ cells
13 106 lineage negativemouse bonemarrow cells were nucleofected using the
mouseMacrophage Nucleofector Kit (Amaxa) with program Y-01 and 100 pmol
siRNA.Cellswere thencultured inserum-freemedium(Xvivo-15) in thepresence
of cytokines (SCF, 100 ng/ml; TPO, 100 ng/ml; Flt 3 Ligand, 100 ng/ml). Twenty-
four hours postnucleofection, the cells were analyzed by flow cytometry.
Statistics
Statistical significance was assayed by Student’s t test and one-way Anova;
*p < 0.05; **p < 0.01; ***p < 0.005; ns, not significant.
SUPPLEMENTAL DATA
The Supplemental Data include seven figures, Supplemental Experimental
Procedures, and Supplemental References and can be found with this
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5909(08)00577-8.
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